Skip to main content
Key Facts
Chief Executive Officer:
Lamberto Andreotti
New York City
Web Address:
NYSE Listing:
Net Sales:
$15.9 billion in 2014
R&D Investment:
$4.5 billion which included the discovery and development of new medicines for patients
2014 Largest-Selling Products:
ABILIFY®, $2.0 billion
ORENCIA® $1.7 billion
SPRYCEL® $1.5 billion
SUSTIVA® franchise, $1.4 billion
BARACLUDE®, $1.4 billion
REYATAZ®, $1.4 billion
YERVOY® $1.3 billion
Selected Key Products:
ABILIFY® (aripiprazole)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate)
BARACLUDE® (entecavir)
ELIQUIS® (apixaban)
ERBITUX® (cetuximab)
NULOJIX® (belatacept)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUSTIVA® (efavirenz)
YERVOY® (ipilimumab)
Principal Locations:
Worldwide Facilities

Please click on the product links to see the Full Prescribing Information for ABILIFY®, ATRIPLA®, BARACLUDE®, ELIQUIS®, ERBITUX®, NULOJIX®, OPDIVO®, ORENCIA®, PLAVIX®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, ELIQUIS®, NULOJIX®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction and Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest.

February, 2014

© 2015 Bristol-Myers Squibb Company Legal Notice   »   Privacy Policy   »  Trademarks